Palo Alto – January 6, 2017 – Cooley advised Aurinia Pharmaceuticals on its $28.75 million public offering of 12,777,775 units of the company. Each unit consists of one common share of the company and one-half of one common share purchase warrant. The underwriters exercised their option to purchase $3.75 million worth of additional units.
Aurinia, which is headquartered in Victoria, British Columbia and trades on the NASDAQ Global Market under the symbol “AUPH,” is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.